EYEWITNESS NEWS (WBRE/WYOU) — The U.S. Food and Drug Administration (FDA) approved a Buprenorphine treatment option for opioid addiction. According to the FDA, Brixadi is an extended-release injection for use under the skin (subcutaneously) to treat moderate to severe opioid use disorder (OUD). Brixadi is available in two forms, a weekly injection for patients who […]